Aseptika Ltd (Cambridgeshire, UK) is pleased to announce it has been awarded a grant to undertake a randomised controlled trial (RCT) of its asthma management solution for children who have moderate-to-severe asthma and are treated in specialist paediatric centres in NHS hospitals.
Asthma affects 1.1 million children in the UK. Most can successfully manage their asthma with support from their GPs, but 10% have such severe asthma that they require specialist care by paediatricians in dedicated out-patient clinics and can have frequent asthma attacks.
The Asthma⁺me solution has been co-designed with a leading NHS Children’s Hospital, to support the parents or carers of these children. This includes a combination of: education sessions, inhaler-use tracking devices, lung-function monitor, in-built symptom checkers, education syllabus to learn as a family, electronic care plan and the ability to push data to their clinicians to become part of their electronic patient records.
Asthma⁺me was developed with support from the SBRI Healthcare pre-procurement programme to meet defined needs of the NHS. An initial feasibility trial with parents and patients showed a significant increase in their confidence to self-care and knowledge of how to manage asthma attacks.
This further funding under the “SME support to evaluate innovative medical technologies (Round 2)” theme from Innovate UK will be invaluable in supporting the company to generate the clinical and health economics evidence required for the commissioners of children’s services to make Asthma⁺me available to children on the NHS.
The Asthma⁺me solution will be shown internationally at the upcoming Arab Health 2019 in Dubai, where Activ8rlives (Aseptika Limited) will be exhibiting as part of the UK Pavilion in Hall 7: C53.
